Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCommunity-Care Vyvgart Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentCommunity-CarePolicy N/A

    Vyvgart (efgartigimod alfa) Coverage Criteria

    Customize your policy alerts

    Sign up for all Community-Care policy alerts

    Know when Community-Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical benefit medication policy governing prior authorization and coverage of Vyvgart for generalized myasthenia gravis, including initial and continuation criteria, quantity limits, authorization duration, and applicable coding.

    Policy Summary
    PayerCommunity-Care
    PolicyVyvgart (efgartigimod alfa) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization under the medical benefit and document all applicable initial or continuation approval criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    MGFA II-IVInitial disease severity
    MG-ADL ≥5Initial symptom score
    12 vialsQuantity per 28 days
    8 fillsMaximum annual fills
    1 year

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Authorization period
    J9332Applicable HCPCS

    Coverage Criteria

    Initial Therapy Criteria

    Covered for initial approval when all of the following are met.

    Initial therapy for generalized myasthenia gravis

    • Provider and diagnosis

      • The drug is prescribed by, or in consultation with, a neurologist.
      • The member has generalized myasthenia gravis.
    • Disease severity and functional impairment

      • The member has Myasthenia Gravis Foundation of America (MGFA) Class II to IV disease.MGFA Class II to IV
      • The member has a Myasthenia Gravis Activities of Daily Living (MG-ADL) total score of at least 5.MG-ADL total score ≥ 5
    • Prior treatment trials

      • A trial of an acetylcholinesterase inhibitor was ineffective, contraindicated, or not tolerated.
      • ONE of the following trials

        • A trial of an oral corticosteroid was ineffective, not tolerated, or contraindicated.
        • A trial of an oral non-steroidal immunosuppressant was ineffective, not tolerated, or contraindicated.
    • Concomitant biologic therapy

      • Vyvgart will not be used in combination with other biologic therapies for myasthenia gravis.

    Continuation Therapy Criteria

    Covered for continuation therapy when all of the following are met.

    Continuation therapy for generalized myasthenia gravis

    • The member has a documented diagnosis of generalized myasthenia gravis.
    • There is an attestation of a positive clinical response to therapy.
    • Vyvgart will not be used in combination with other biologic therapies for myasthenia gravis.

    Vyvgart (efgartigimod alfa) is not covered when used in combination with other biologic therapies for myasthenia gravis. This exclusion applies to both initial and continuation therapy.

    Coding and Coverage Parameters

    Covered HCPCS CodesHCPCSCovered
    J9332Injection, efgartigimod alfa-fcab, 2mg
    MGFA Classification
    ClassificationMyasthenia Gravis Foundation of America (MGFA) Class II to IV
    Minimum classificationClass II
    Maximum classificationClass IV
    MG-ADL Total Score
    Minimum qualifying scoreMG-ADL total score ≥ 5
    MeasureMyasthenia Gravis Activities of Daily Living (MG-ADL) total score
    Approval useRequired for initial approval

    Provider Actions and Authorization Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required under the medical benefit before coverage of Vyvgart (efgartigimod alfa) for generalized myasthenia gravis. Approval is subject to the applicable initial or continuation coverage criteria and authorization limits.

    Step Therapy

    Required Prior Treatment Trials

    Initial approval requires documented prerequisite treatment trials for generalized myasthenia gravis. The trial must have been ineffective, not tolerated, or contraindicated as specified below.

    • An acetylcholinesterase inhibitor must have been ineffective, contraindicated, or not tolerated.
    • At least one of the following must have been ineffective, not tolerated, or contraindicated: an oral corticosteroid or an oral non-steroidal immunosuppressant.

    Clinical Background

    This policy assesses generalized myasthenia gravis using both disease severity and functional impact. Initial approval requires MGFA Class II to IV disease and an MG-ADL total score of at least 5. The MG-ADL is an eight-item patient-reported scale that evaluates myasthenia gravis symptoms and their effects on daily activities; each item is scored from 0 to 3, for a total range of 0 to 24.

    Definitions and Assessment Measures

    Myasthenia Gravis Activities of Daily Living (MG-ADL)
    PurposeAssesses myasthenia gravis symptoms and their effects on daily activities
    StructureEight-item patient-reported scale
    Item scoringEach item is scored from 0 to 3
    Total score range0 to 24
    Clinically Meaningful MG-ADL Difference
    Clinically meaningful differenceA reduction of two points in the MG-ADL total score
    Score changeTwo-point reduction

    Initial Therapy Criteria

    Initial Therapy Criteria

    Initial coverage requires all listed criteria.

    Vyvgart initial therapy

    • The drug is prescribed by, or in consultation with, a neurologist.
    • The member has generalized myasthenia gravis.
    • The member has Myasthenia Gravis Foundation of America (MGFA) Class II to IV disease.MGFA Class II to IV
    • The member has a Myasthenia Gravis Activities of Daily Living (MG-ADL) total score of at least 5.MG-ADL total score ≥ 5

    Continuation Therapy Criteria

    Continuation Therapy Criteria

    Continuation coverage requires all of the following.

    Vyvgart continuation therapy

    • The member has a documented diagnosis of generalized myasthenia gravis.
    • There is an attestation of a positive clinical response to therapy.
    • Vyvgart will not be used in combination with other biologic therapies for myasthenia gravis.

    Step Therapy Requirements

    StepRequired treatment trialQualifying outcome
    1Trial of an acetylcholinesterase inhibitor and a trial of one of the following: an oral corticosteroid or an oral non-steroidal immunosuppressant.The acetylcholinesterase inhibitor trial was ineffective, contraindicated, or not tolerated; the oral corticosteroid or oral non-steroidal immunosuppressant trial was ineffective, not tolerated, or contraindicated.

    Quantity Limits

    efgartigimod alfa Quantity Limits
    Quantity per 28 days12 vials
    Volume per 28 days240 mL
    Maximum annual fills8 fills per year
    Policy Summary
    PayerCommunity-Care
    PolicyVyvgart (efgartigimod alfa) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization under the medical benefit and document all applicable initial or continuation approval criteria.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Coverage ParametersProvider Actions and Authorization RequirementsClinical BackgroundDefinitions and Assessment MeasuresInitial Therapy CriteriaContinuation Therapy CriteriaStep Therapy RequirementsQuantity Limits
    Quantity Limit
    Vial quantity12 vials
    Volume240 mL
    Authorization periodPer 28 days
    Annual Fill Limit
    Maximum fills8 fills
    Time periodPer year
    Policy limitMaximum 8 fills per year
    Documentation Required

    Initial Authorization Documentation

    Submit initial authorization documentation confirming the diagnosis and clinical severity of generalized myasthenia gravis, along with supporting clinical records and prescribing information.

    • Prescribed by or in consultation with a neurologist.
    • Diagnosis of generalized myasthenia gravis.
    • Myasthenia Gravis Foundation of America (MGFA) Class II to IV.
    • Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score of ≥ 5.
    • Supporting documentation of the required prior treatment trials and their outcomes, contraindications, or intolerance.
    Documentation Required

    Continuation Documentation

    For continuation authorization, submit documentation supporting ongoing treatment for generalized myasthenia gravis and attest to a positive clinical response to therapy.

    • Diagnosis of generalized myasthenia gravis.
    • Attestation of a positive clinical response to therapy.
    • Confirmation that Vyvgart will not be used in combination with another biologic therapy for myasthenia gravis.
    Denial Risk

    Initial Criteria Not Met

    Initial coverage may be denied when the required clinical criteria or prerequisite treatment trials are not met or when the required supporting documentation is not submitted.

    • The patient does not have generalized myasthenia gravis, MGFA Class II to IV disease, or an MG-ADL total score of ≥ 5.
    • The prescriber requirement or required prior treatment trials is not satisfied.
    • Vyvgart will be used in combination with another biologic therapy for myasthenia gravis.
    Denial Risk

    Concurrent Biologic Therapy

    Coverage may be denied when Vyvgart is used in combination with another biologic therapy for myasthenia gravis. This restriction applies to both initial and continuation therapy.

    • Confirm that no other biologic therapy for myasthenia gravis is being used concurrently.
    Denial Risk

    Continuation Response Not Established

    Continuation coverage may be denied when a positive clinical response to therapy is not established or when continuation criteria are otherwise not met.

    • No attestation of a positive clinical response is submitted.
    • The patient does not have a documented diagnosis of generalized myasthenia gravis.
    • Vyvgart will be used in combination with another biologic therapy for myasthenia gravis.
    Billing Rule

    Quantity Limit Exceeded

    If approved, quantity is limited to 12 vials per 28 days (240 mL per 28 days), with a maximum of 8 fills per year. Claims or requests exceeding these limits may be denied or require correction.

    • Quantity limit: 12 vials per 28 days.
    • Equivalent volume limit: 240 mL per 28 days.
    • Maximum: 8 fills per year.
    MeasureMG-ADL total score
  1. Required prior treatment trials

    • A trial of an acetylcholinesterase inhibitor was ineffective, contraindicated, or not tolerated.
    • ONE of the following

      • A trial of an oral corticosteroid was ineffective, not tolerated, or contraindicated.
      • A trial of an oral non-steroidal immunosuppressant was ineffective, not tolerated, or contraindicated.
  2. Vyvgart will not be used in combination with other biologic therapies for myasthenia gravis.